| Literature DB >> 15230729 |
Y Ebihara1, M Miyamoto, T Shichinohe, Y Kawarada, Y Cho, A Fukunaga, S Murakami, H Uehara, H Kaneko, H Hashimoto, Y Murakami, T Itoh, S Okushiba, S Kondo, H Katoh.
Abstract
The transcription factor E2F-1, a downstream regulator of the p16-cyclinD-Rb pathway, is required for cell cycle progression. Evidence shows that overexpression of E2F-1 can either promote or inhibit the development of tumors, depending on tissue or experimental conditions. However, the clinical impact of E2F-1 expression on esophageal squamous cell carcinoma (ESCC) remains unknown. To analyze E2F-1 expression in ESCC, we investigated the immunoreactivity of E2F-1 and its correlation with clinicopathological features in 122 patients who underwent surgical resection for ESCC. Positive E2F-1 immunostaining was detected in 73 patients (59.8%). Positive E2F-1 immunostaining correlated positively with pathologic stage (P = 0.0103), p-Grade (P = 0.0014) and pT (P = 0.0192). The overall survival rate was worse in patients with E2F-1-positive tumors than in patients with E2F-1-negative tumors (P = 0.0290). Over-expression of E2F-1 is associated with tumor progression and a worse prognosis after surgery in ESCC.Entities:
Mesh：
Substances：
Year: 2004 PMID： 15230729 DOI： 10.1111/j.1442-2050.2004.00393.x
Source DB: PubMed Journal: Dis Esophagus ISSN： 1120-8694 Impact factor: 3.429